AstraZeneca Pharmaceuticals LP
NEWS
Breztri Aerosphere is a triple combination drug of budesonide, glycopyrronium and formoterol fumarate.
AstraZeneca said the FDA awarded the designation to Farxiga to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.
The Phase III NEPTUNE trial assessed the combination treatment as a first-line treatment in an “all-comers population,” with the primary analysis population being patients with a high tumor mutational burden.
AstraZeneca announced that its Phase III DAPA-HF clinical trial of Farxiga (dapagliflozin) met its primary endpoint in decreasing cardiovascular death or the worsening of heart failure compared to placebo.
As summer winds its way to an end, biopharmaceutical companies continue to conduct clinical trials and release news related to them. Here’s a look at last week’s clinical trial headlines.
The new designation granted to Calquence marks the 10th such designation the company has earned since 2014, AstraZeneca said.
For the second time in a Phase III trial, Lynparza met its endpoints as a potential first-line treatment for ovarian cancer.
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look.
Tagrisso improved overall survival in lung cancer patients.
JOBS
IN THE PRESS